SGBCC 2025 – Webcasts
You may find the webcasts of the 19th St.Gallen International Breast Cancer Conference below.
Scientific Sessions
Opening Ceremony: Welcome, Awards and Award Lectures
Welcome on behalf of St.Gallen Oncology Conferences (SONK), Swiss Group for Clinical Cancer Research (SAKK) and on behalf of the International Breast Cancer Study Group (ETOP IBCSG Partners Foundation)
Beat Thürlimann (Switzerland)
Welcome on behalf of the Austrian Breast Cancer Study Group (ABCSG), Medical University of Vienna, and co-operating partners from all over the world
Michael Gnant (Austria)
Introduction of the Hansjoerg Senn Memorial Lecture – handing over the St.Gallen Breast Cancer Award 2025
Walter Weber (Switzerland)
The Hansjoerg Senn Memorial Lecture 2025
My Personal Experience: Changing Surgery for Breast Cancer
Armando Giuliano (USA)
Closing
Giuseppe Curigliano (Italy)
Ouverture: Glancing into the future – moving up innovative agents from mBC to eBC
Chairs: Giuseppe Curigliano / Harold Burstein
Breakthroughs and innovation in advanced disease – arriving in the curable setting soon?
Giuseppe Curigliano (Italy)
Novel endocrine agents – how to use and not abuse them in early breast cancer
Fabrice Andre (France)
New anti-HER2 approaches – moving up to the (neo)adjuvant setting?
Javier Cortes (Spain)
ADCs: new wonder drugs for early HR+ and TN breast cancer?
Sara Tolaney (United States of America)
Session 1: Liquid biopsy: What kind of evidence for clinical utility?
Chairs: Sherene Loi / Nick Turner / Wolfgang Janni
The technology of detecting ctDNA: exuberance, and caution
Nick Turner (United Kingdom)
Clinical Utility of liquid biopsy for screening and MRD detection
Francois-Clement Bidard (France)
Perspectives – Adapting clinical trials to include ctDNA: what should be the endpoint?
Wolfgang Janni (Germany)
Discussion Moderator: Sherene Loi
Session 2: HER2positive Early Breast Cancer – mission accomplished?
Chairs: Martine Piccart / Carsten Denkert / Binghe Xu
20th Anniversary of adjuvant trastuzumab: reflections on a breakthrough moment
Martine Piccart (Belgium)
HER2 testing: Where we are 20 years later?
Carsten Denkert (Germany)
Risk adapted neoadjuvant and adjuvant therapy for HER2+ eBC
Nadia Harbeck (Germany)
Management of residual disease HER2-positive eBC
Komal Jhaveri (United States of America)
Discussion Moderator: Nadia Harbeck
Session 3: Minimizing the burden of cancer treatments: more tailoring for early breast cancer
Chairs: David Cameron / Jens Huober / Shigehira Saji
When can we safely withhold radiotherapy and even surgery?
Charlotte Coles (United Kingdom)
Which older patients truly need chemotherapy?
Hans Wildiers (Belgium)
Pyrrhic victory? Are newer approaches causing more harm than good?
Mafalda Oliveira (Spain)
Discussion Moderator: David Cameron
Discussion Participant: Tanja Spanic
Session 4: Optimizing locoregional treatments of the breast
Chairs: Walter Weber / Zhiming Shao / Monica Morrow
Why should we prevent mastectomies?
Jana de Boniface (Sweden)
Tailoring radiotherapy: Partial breast and hypofractionation, DCIS and molecular markers
Daniela Kauer-Dorner (Austria)
Breast surgery after neoadjuvant systemic treatment
Viviana Galimberti (Italy)
Breast reconstruction and quality of life
Christine Solbach (Germany)
Discussion Moderator: Jana de Boniface
Debate 1: Node-positive breast cancers warrant regional nodal irradiation
Chair: Walter Weber
For: Shelley Potter, Orit Kaidar-Person
Against: Monica Morrow, Philip Poortmans
Session 5: Nuances in adjuvant therapy for ER+ breast cancer
Chairs: Harold Burstein / Michael Gnant / Meteb Al-Foheidi
Crawling towards cure – small steps of clinical benefit in HR+ (De-escalation, combination, new drugs? SERDs?)
David Cameron (United Kingdom)
Which ER+ tumors still require chemotherapy?
Kevin Kalinsky (United States of America)
The long and winding road of individualized endocrine therapy in premenopausal women
Prudence Francis (Australia)
How long is long enough? Duration of endocrine therapy in view of locoregional treatment de-escalation
Terry Mamounas (United States of America)
Lobular breast cancer: unique approaches?
Marie-Jeanne Vrancken-Peeters (Netherlands)
Multi-omic subtyping and precision-guided therapy of luminal breast cancer
Zhiming Shao (China)
Which tumors warrant adjuvant CDK4/6 inhibitor therapy?
Angela De Michele (United States of America)
Which ER+ cancers will warrant immunotherapy approaches?
Marleen Kok (Netherlands)
Discussion Moderator: Harold Burstein
Session 6: Bringing artificial intelligence to the breast cancer clinic
Chairs: Fabrice Andre / Nadia Harbeck / Jacob Kather
What is the role of AI in breast pathology?
Jakob Kather (Germany)
What is the role of AI in planning radiation therapy?
Gerd Fastner (Austria)
Discussion Moderator: Jacob Kather
Session 7: Is it time to update our imaging and diagnostic approach in early breast cancer?
Chairs: Isabel Rubio / Bahadir Gulluoglu / Eriko Tokunaga
Where does PET imaging belong in initial staging?
Isabel Rubio (Spain)
What is the role of MRI in the initial presurgical work up?
Bahadir Gulluoglu (Turkey)
Most cancers (lung, colorectal, ovarian, prostate, leukemia, lymphoma) have surveillance studies: is it time to re-think our approach in breast cancer?
Jens Huober (Switzerland)
Discussion Moderator: Bahadir Gulluoglu
Session 8: Hereditary Breast Cancer
Chairs: Christian Singer / Andrew Tutt / Sara Brucker
Genetic testing: risk-adapted approaches, or make it universal?
Shani Paluch-Shimon (ISR)
What do we actually achieve with mastectomy in terms of outcome?
Kelly Metcalfe (Canada)
Risk reducing surgery: are nerve- or nipple-sparing techniques appropriate in mutation carriers?
Judy Boughey (United States of America)
Alternatives to risk reducing surgery – Intense surveillance or preventive therapies
Christian Singer (Austria)
Discussion Moderator: Andrew Tutt
Session 9: Optimizing locoregional management: the axilla
Chairs: Judy Boughey / Philip Poortmans / Chiun-Sheng Huang
Who can avoid upfront sentinel node and axillary surgery in node-negative and node-positive presentations
Cicero Urban (Brazil)
Axillary surgery in inflammatory breast cancer, local recurrence, or stage IV cancer
Maria Joao Cardoso (Portugal)
Axillary surgery after neoadjuvant chemotherapy
Walter Weber (Switzerland)
Nodal irradiation after neoadjuvant chemotherapy
Anusheel Munshi (India)
Discussion Moderator: Maria Joao Cardoso
Session 10: Designing clinical trials that are patient-centered, purposeful, and pragmatic
Chairs: Meredith Regan / Mafalda Oliveira / Sung Yong Kim
Strenghts and limitations of clinical trial design
Meredith Regan (United States of America)
Meaningful Measures – the clinicians perspective [who chooses clinical trial populations – only industry?]
David Cameron (United Kingdom)
Regulatory perspective – overextrapolating high risk derived data to average risk populations
Francesco Pignatti (European Medicines Agency)
Patient perspective – what do WE really need?
Tanja Spanic (Slovenia)
Discussion Moderator: Meredith Regan
Special Lecture: SABCS 2024 Highlights
Chairs: Giuseppe Curigliano / Michael Gnant
2024 Clinical research highlights for early and late breast cancer
Virginia Kaklamani (United States of America)
Debate 2: Oligometastatic breast cancer is curable
Chair: Beat Thürlimann
For: Catherine M. Kelly, Virginia Kaklamani
Against: Stephen Chia, Barbara Pistilli
Session 11: Addressing the needs of young breast cancer patients
Chairs: Prudence Francis / Zefei Jiang / Heba Gamal
Breast Cancer during pregnancy
Cristina Saura (Spain)
Fertility preservation and pregnancy after breast cancer
Matteo Lambertini (Italy)
Sexual health in breast cancer survivors
Laura Michel (Germany)
Addressing long-term toxicities from breast cancer treatments and evidence based approaches for healthy living in Breast Cancer
Cynthia Villarreal-Garza (Mexico)
Discussion Moderator: Prudence Francis
Session 12: Systemic therapy for early triple-negativ breast cancer
Chairs: Sibylle Loibl / Lisa Carey / Virginia Kaklamani
How much immunotherapy is enough?
Sherene Loi (Australia)
Quantifying residual disease, and understanding its biology and clinical implications
William Fraser Symmans (United States of America)
Adjuvant therapy after pCR; adjuvant therapy with residual cancer
Lisa Carey (United States of America)
Does everyone with TNBC need chemotherapy? Which cancers – by stage or biology – do not?
Hope Rugo (United States of America)
Beyond PARP & BRCA: Next generation approaches to HRD
Andrew Tutt (United Kingdom)
Have we all become immunooncologists – long term side effects and how to handle them
Shaheena Dawood (United Arab Emirates)
Discussion Moderator: Hope Rugo
SGBCC Academy
Stefan Aebi: Prevention of Bone disease in Early Breast Cancer
Zsuzsa Bago-Horvath: State-of-the-art in breast pathology
Denisse Bretel Morales: State-of-the art in breast surgery
Sara Brucker: How to treat side effects of endocrine therapy
Shaheena Dawood: Neoadjuvant and adjuvant therapy of HER2 positive EBC
Heba Gamal: How to treat locally advanced breast cancer
Yongmei Yin: Patient reported outcomes – how to involve survivorship?
Orit Kaidar-Person: Indication for radiotherapy after breast-conserving therapy and mastectomy
Catherine M. Kelly: Managing side effects of chemotherapy
Shelley Potter: Benefits and risks of prophylactic surgery
Elzbieta Senkus-Koniefka: Multidisciplinary setup of breast centers
Christine Solbach: Type and timing of breast reconstruction in the setting of post-mastectomy radiotherapy
Tanja Spanic: Importance of survivorship and patient advocay
Sung Yong Kim: How to manage early triple-negative breast cancer
Eriko Tokunaga: State-of-the-art and challenges in diagnostic imaging
Walter Weber: Current indications for axillary dissection
